Literature DB >> 11263951

Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia.

A L Coker1, R B Russell, S M Bond, L Pirisi, Y Liu, M Mane, N Kokorina, T Gerasimova, P L Hermonat.   

Abstract

Adeno-associated virus (AAV) is a ubiquitous human helper-dependent parvovirus which may interact with human papillomaviruses (HPV) to modify a woman's risk of cervical neoplasia. This analysis was nested in a cohort study of low-income women receiving Pap smears as part of their family planning services. We selected cases (55 with high-grade cervical squamous intraepithelial lesions (HSIL) and 162 with low-grade LSIL) and controls (96 women with normal cervical cytology) and analyzed cervical DNA for AAV, using PCR amplification/dot blot hybridization, and HPV, using hybrid capture I. AAV positivity was associated with a significantly reduced risk of HSIL (age and HPV-adjusted odds ratio (aOR) = 0.32) yet not with LSIL (aOR = 0.78); 53.8% of HSIL, 66.9% of LSIL, and 70.7% of controls were AAV+. AAV appears to interact with HPV to reduce SIL risk; relative to the HPV-/AAV+ exposure, the respective aORs for HSIL and HPV+/AAV-, HPV+/AAV+, and HPV-/AAV+ were 17.0, 6.9, and 3.5. AAV+ was not associated with age, race, HPV status, or sexual or reproductive risk factors. These results strongly suggest that AAV may play a protective or inhibitory role in late stage cervical carcinogenesis. This conclusion needs to be verified in additional epidemiologic studies. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11263951     DOI: 10.1006/exmp.2000.2347

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  13 in total

1.  HPV E1 up-regulates replication-related biochemistries of AAV Rep78.

Authors:  Sarmistha Bandyopadhyay; Maohua Cao; Yong Liu; Paul L Hermonat
Journal:  Virology       Date:  2010-04-07       Impact factor: 3.616

2.  Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.

Authors:  Terence R Flotte
Journal:  Mol Ther       Date:  2013-11       Impact factor: 11.454

3.  Adeno-associated virus type 2 increases proteosome-dependent degradation of p21WAF1 in a human papillomavirus type 31b-positive cervical carcinoma line.

Authors:  Samina Alam; Ellora Sen; Heidi Brashear; Craig Meyers
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 4.  The interaction between human papillomavirus and other viruses.

Authors:  J T Guidry; R S Scott
Journal:  Virus Res       Date:  2016-11-05       Impact factor: 3.303

5.  AAV Infection: Protection from Cancer.

Authors:  Arun Srivastava; Barrie J Carter
Journal:  Hum Gene Ther       Date:  2016-11-10       Impact factor: 5.695

6.  Human papillomavirus, cytomegalovirus, and adeno-associated virus infections in pregnant and nonpregnant women with cervical intraepithelial neoplasia.

Authors:  M Grce; K Husnjak; M Matovina; N Milutin; L Magdic; O Husnjak; K Pavelic
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

7.  Infection and cervical neoplasia: facts and fiction.

Authors:  Wael I Al-Daraji; John Hf Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-04-28

8.  Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression.

Authors:  Anthony N van den Pol; Koray Ozduman; Guido Wollmann; Winson S C Ho; Ian Simon; Yang Yao; John K Rose; Prabhat Ghosh
Journal:  J Comp Neurol       Date:  2009-10-20       Impact factor: 3.215

Review 9.  Human papillomavirus and cervical cancer.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

10.  Cervical cancer isolate PT3, super-permissive for adeno-associated virus replication, over-expresses DNA polymerase delta, PCNA, RFC and RPA.

Authors:  Bum Yong Kang; Hong You; Sarmistha Bandyopadhyay; Nalini Agrawal; Russell B Melchert; Alexei G Basnakian; Yong Liu; Paul L Hermonat
Journal:  BMC Microbiol       Date:  2009-04-23       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.